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is an equally efficacious alternative to urinary derived FSH, Menopur®. One differ-
ences between these products is their delivery devices; Gonal f® is provided as a 
multidose pen, Menopur® in vials or multidose preparation, and Bemfola® as a fixed 
dose pen. The aim of this study was to determine the impact of delivery device on 
drug wastage and associated cost. Methods: A retrospective analysis of Gonal-f® 
and Menopur® prescription and usage data from five UK infertility clinics was 
conducted to identify the level of wastage occurring from IVF cycles. Data collected 
included: number IVF cycles conducted in previous 12 months; daily dose; length 
of treatment; dose adjustment following ultrasound scan and FSH formulation(s) 
prescribed. The drug wastage for each patient was calculated and results compared 
to the potential Bemfola® wastage for these patients. The wastage cost was then 
determined using NHS list prices. Results: A total of 4724 IVF cycles were incor-
porated into the analysis. Of the 4078 Gonal-f® cycles, overall drug wastage was 
650,775IU (5.7% of total dose prescribed) equating to 160IU per patient. For the 646 
Menopur® cycles the wastage was 190,163IU (11.6% of total dose prescribed) equat-
ing to 294IU per patient. Had Bemfola® been used in these patients, the wastage 
would have been reduced to 104IU and 61IU per patient respectively. The use of 
Bemfola®, across all cycles, results in a drug wastage reduction of 376,800IUs and an 
associated cost saving of £100,011. Extrapolating this data to the annual number of 
UK IVF cycles results in a potential cost saving of £1,157,579. ConClusions: Using 
Bemfola® as an alternative to Gonal-f® or Menopur® can potentially reduce drug 
wastage and associated costs to both patients and the NHS.
PIH12
Cost-EffECtIvEnEss AnAlysIs of BotulInum toxIn tyPE A trEAtmEnt 
for CErEBrAl PAlsy
Yagudina R, Kulikov A, Ugrekhelidze D
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: To conduct a cost-effectiveness analysis of abobotulinumtoxinA+ 
standard therapy (ST), onabotulinumtoxinA+ST and standard therapy solely in 
patients with spastic cerebral palsy in Russia for 2-year period. Standard therapy 
includes centrally acting muscle relaxant, physiotherapy, casting and ortho-
sis. Methods: A decision tree model used to simulate the effects of abobotuli-
numtoxinA, onabotulinumtoxinA and standard therapy. The data on drugs efficacy 
(measured as proportion of patients with spastic forms of cerebral palsy, avoided 
orthopedic surgery at 2nd year of therapy) was obtained from available clinical tri-
als. In the long term, surgery in older children with cerebral palsy have lower risk 
of recurrence compared with the operations carried out in early childhood. In this 
regard, there is a particular importance of botulinum toxin therapy effect on the 
likelihood of reducing the frequency of the orthopedic surgeries or postponing them 
at a later period by reducing spasticity and prevent contractures. The following costs 
were taken into account: the costs of pharmacotherapy, inpatient and outpatient 
care, costs of adverse events, sanatorium-resort medical care, casting orthopedic 
surgeons, disability pensions, disable child care benefit. Results: It was revealed 
that the abobotulinumtoxinA+standard therapy helps to avoid surgical intervention 
in 93% of patients compared to 90% of patients with onabotulinumtoxinA+standard 
therapy and for 48% of patients with standard therapy. It was found that the regi-
men abobotulinumtoxinA+standard therapy has the lowest cost-effectiveness ratio 
(11,509 RUB/215 $) in comparison with drug therapy onabotulinumtoxinA+standard 
therapy (12 872 RUB/ 238 $) and standard therapy with a centrally acting mus-
cle relaxant without BTA (27 715 rubles/467 $) by the end of 2 years of treat-
ment. ConClusions: Treatment scheme abobotulinumtoxinA+standard therapy 
is considered the most cost-effective one for spastic cerebral palsy therapy in the 
Russian Federation compared with onabotulinumtoxinA+standard therapy and 
standard therapy solely.
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objeCtives: To estimate the lifetime indirect cost of childhood overweight and 
obesity for Germany. Methods: An incidence-based lifetime cohort model was 
developed using Markov modelling approach. The model consisted of two parts: (a) 
Model I used German data on prevalence of BMI categories (normal weight, over-
weight and obesity) during childhood and adolescence to evaluate BMI trajectories 
before the age of 18; and (b) Model II analysed the lifetime BMI trajectories based on 
the history of childhood BMI and estimated lifetime excess indirect cost attribut-
able to childhood overweight and obesity. The model used data from the German 
Interview and Examination Survey for Children and Adolescents (KiGGS) and the 
German Microcensus 2009. Indirect costs were defined as the opportunity cost of 
lost productivity due to morbidity or early mortality and were identified through 
a systematic literature review. Results: Our analysis showed that the majority 
of overweight and obese children remained in the same BMI category during their 
adult life, resulting in significant indirect costs over the lifetime. We estimated that 
overweight and obesity during childhood resulted in an excess lifetime cost per 
person of 4,209 EUR (discounted at 3%) for men and 2,445 EUR (discounted at 3%) 
for women. For the current prevalent German population, the excess lifetime cost 
of overweight and obesity was 145 billion EUR (discounted at 3%). ConClusions: 
Our study showed that overweight and obesity during childhood results in signifi-
cant economic burden on the society. Therefore, cost-effective strategies targeted 
at reducing the prevalence of obesity during the early years of life can significantly 
reduce both healthcare and non-healthcare costs over the lifetime.
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IBM SPSS for windows statistical software version 20 (SPSS Inc, Chicago, USA). Data 
was presented using descriptive statistics (i.e. numbers, percentages). Results: A 
total of 450 questionnaires were administered to the respondent. After exclusion, 
finally 378 respondents were included. Majority of the respondents (94%) accepted 
their habit of practicing self-medication. In this study, 86% of the respondents were 
found to have habit of advising medicines to others, while 70% respondents tried 
medicines according to their friend’s suggestion. Most common reason cited for self-
medication was found to be convenience (42%), followed by quick relief (21%), time 
saving (13%), economical (10%) and others (14%). ConClusions: Self-medication 
is highly prevalent in pharmacy students. One potential reason could be the easy 
availability of wide range of drugs without prescription.
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rIsk fACtors And CAusEs of IntrAutErInE dEAtH
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Oláh A3
1University of Pécs, Szombathely, Hungary, 2University of Pécs, Zalaegerszeg, Hungary, 
3University of Pécs, Pécs, Hungary, 4University of Pécs, Kaposvár, Hungary
objeCtives: To measure all those risk factors of danger that may lead to intrau-
terine death. To introduce the frequency of intrauterine death related to maternal 
origins and the diseases of the foetus. Methods: Our research was carried out in 
Teaching Hospital Markusovszky, Szombathely. We examined 50 pregnancies fol-
lowed by intrauterine death by document analysis between the period of 1 January, 
2007 and 31 December 2014. We applied average and frequency calculation within 
descriptive statistical methods for analyzing data. Defining the relation between the 
two variants, we calculated chi2 probability (p< 0,05). Results: Significant differ-
ences can be seen between incidence rate of foetal death regarding singular preg-
nancies CI 0,78-0,97 and multiple pregnancies CI 0,02 - 0,21; as well as in terms of 
foetal death between undeveloped foetus CI 0,23-0,49 and developed foetus between 
CI 0,50-0,76. Our examination found that in most cases there were maternal pre-
disposing factors, operation carried out previously on the mothers, and circulatory 
diseases (p> 0,05) which were followed by endocrin diseases (p> 0,05). The most 
frequent predisposing factors of the foetus were placenta abnormalities in particu-
lar placenta abruptio. According to our examination, the riskiest period in terms 
of intrauterine death is between 25-30 gestational weeks. There were 19 (38%) boy 
and 33 (66%) girl foetus morti. The most frequent intrauterine deaths are among 
the foeti of 501-1000 grams and 31-35 centimeters. According to our examination 
maternal predisposing factors were hypoxia, multiple pregnancy, obesity, hyper-
thyroidism and smoking. The following risk factors of foetus occured: dysmaturity, 
abruptio placentae, polihydramnion, premature birth, developmental abnormality 
of the foetus. ConClusions: For the decrease in number of intrauterine deaths, 
it would be extremely important to record accurate maternity anamnesis. In our 
view, with early identification of exposure to risk, prevention of complications and 
its early identification, stillbirths can be reduced
IndIvIduAl’s HEAltH – Cost studies
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AnAlysIs for tHE nAtIonAl HEAl systEm In PortugAl
Lopes F1, Bombas T2, Ambrósio P3, Laires PA1
1Merck Sharp & Dohme, Oeiras, Portugal, 2Centro Hospitalar e Universitário de Coimbra, Coimbra, 
Portugal, 3Merck Sharp & Dohme, Paço d’ Arcos, Portugal
objeCtives: To develop an interactive tool to estimate the budget impact of implant 
versus daily oral contraception (OC) use over a 3-year time horizon. Methods: A 
previously developed and published decision-analytic model was adapted to build 
an interactive tool in which users can evaluate the costs of implant and OC use 
over 3-years (healthcare payers’ perspective) for a given population and by custom-
izing some model inputs. Costs associated with a population of women initiating 
each method are calculated at the end of each year and for 3 years cumulatively. 
The model allows method discontinuation throughout time followed by switch to 
another hormonal contraceptive or drop out. Pregnancy and contraceptive costs 
incurred after switching or drop out are allocated to the starting contraceptive 
method. Model inputs: 1) contraceptive methods discontinuation and failure rates; 
2) risk of dropping out contraception and due probability of getting pregnant; 3) 
market share for hormonal contraceptives; 4) pregnancy outcomes probability and 
costs; 5) contraceptive and medical follow-up costs. Model outputs are unplanned 
pregnancies and costs. Default scenario is presented for national level (Portuguese 
sources of data were used when available, including unit costs). Results: National 
default results were calculated for 1000 women. Implant utilization was associated 
with higher costs at the 1st year (due to its acquisition and insertion). For the 2nd, 
3rd year and for cumulative results OC was associated with higher costs due to 
higher risk of unplanned pregnancies. ConClusions: A tool was created to provide 
healthcare stakeholders with the opportunity to perform a customized analysis 
and to make evidence-based decisions considering the economic perspective when 
assessing the most appropriate methods to offer women in the NHS setting. In the 
Portuguese default scenario implant initial acquisition and insertion costs are offset 
by decreased pregnancy related costs, when comparing with OC use during 3 years
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BEmfolA® CAn PotEntIAlly rEduCE drug wAstAgE And AssoCIAtEd 
Costs of IntErtIlIty trEAtmEnt
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objeCtives: Bemfola®, an EMA approved Gonal-f® biosimilar, is a recombinant 
follicle-stimulating hormone (rFSH) used for in-vitro fertilisation (IVF). Bemfola® 
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and available e-library resources considering the associated preventing drug related 
problems and Healthcare Improvement and better care, better patient outcomes, 
and reduced costs.
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EConomIC ImPACt of trEAtIng CHInEsE PostmEnoPAusAl womEn 
wItH 17-ß-EstrAdIol ComBInEd HormonE rEPlACmEnt tHErAPy (Hrt) 
ComPArEd wItH tHE AltErnAtIvE PrACtICEs
Connolly M1, Hu S2, He J2, Yang Y2, Zhang L3
1University of Groningen, Groningen, The Netherlands, 2Shanghai Health Development Research 
Center, Shanghai, China, 3Abbott China, Shanghai, China
objeCtives: In China there is a lack of awareness of HRT as a treatment option to alle-
viate climacteric symptoms apart from herbal or traditional Chinese medicines (CM). 
This study aims to assess economic impact of reimbursing 17-ß-estradiol combined 
HRT from Chinese payer’s perspective. Methods: An economic analysis based on 
Danish Osteoporosis Prevention Study (DOPS) efficacy data was conducted to model 
an assumptive cohort of 100,000 women in 2 comparisons, namely HRT based on 2mg 
17-ß-estradiol and 10 mg Dydrogesterone versus mixed-treatment cohort, (including 
41% no treatment after clinical consultations and 59% treated using CM), and a second 
comparison of HRT versus 100% CM (50,000 for each group). Long-term fracture, car-
diovascular (CV) events and drug procurement costs are evaluated as main outcomes. 
Cost data are obtained from Shanghai Patient Electronic Medical Records. Daily drug 
cost is ¥4.39 for HRT based on the only available 17-ß-estradiol included combina-
tion drug in China and ¥12 for alternative treatment based on the market research. 
5-year continuous treatments with 65% compliance and 10% patients’ copayment 
are reported as base-case scenario. Results: The per person costs to achieve frac-
ture free 5 year for HRT, CM-59%, and CM-100% cohorts was ¥831, ¥1,370, and ¥2,276, 
respectively. The cost per CV event free 5 year for HRT, CM-59%, and CM-100% cohorts 
was ¥814, ¥1,363, and ¥2,275, respectively. The cost savings achieved with HRT com-
pared to CM-59%, and CM-100% cohorts was ¥544 and ¥1453, respectively. Comparing 
the costs for 50,000 women using HRT with CM-59%, and CM-100%, a savings of ¥143 
million and ¥369 million, respectively was achieved. ConClusions: Although the 
willingness for Chinese menopausal women to seek treatment is quite low, treating 
all those who have sought clinical consultations with HRT rather than maintaining 
use of CM may save healthcare expenditure.
PIH18
A Cost-EffECtIvEnEss EvAluAtIon ComPArIng BIosImIlAr BEmfolA to 
gonAl-f for tHE trEAtmEnt of InfErtIlIty In An ItAlIAn ContEst
Ripellino C1, Visentin E1, Gizzo S2, Bühler K3
1IMS Health Information Solutions Medical Research S.r.l, Milan, Italy, 2University of Padua, 
padua, Italy, 3Centre for Gynaecology, Endocrinology and Reproductive Medicine, Ulm and 
Stuttgart, Germany
objeCtives: Bemfola, biosimilar follitropin alfa, has been launched in the 
Italian Market as a treatment for infertility. The aim of this project is to perform 
a cost-effectiveness evaluation comparing Bemfola to Gonal-f in an Italian con-
test. Methods: Starting from “A multi-centre phase 3 study comparing efficacy 
and safety of Bemfola® versus Gonal-f in women undergoing ovarian stimulation 
for IVF” by Rettenbacher et al., a cost-effectiveness model was developed to compare 
costs and efficacies of the two comparators (Bemfola and Gonal-f) in an Italian 
contest. Clinical data on number of subjects, total dose of gonadotropins, pregnan-
cies and liveborn children, OHSS for both first and second cycle of the study by 
Rettenbacher et al. were used to feed the model. Costs related to drugs, DRG for ART, 
specialistic visits and examinations were retrieved from 2015 Italian tariffs. The 
perspective is the NHS one. Costs of Bemfola and Gonal-f arms were divided by the 
efficacies, i.e. live birth rate, in order to obtain an average cost per live birth and ICER 
was also calculated. Results: Gonal-f cost resulted to be € 3,550 whereas Bemfola 
cost resulted to be € 3,483. Efficacy, i.e. live birth rate, associated to Gonal-f was 0.52 
whereas it was 0.47 for Bemfola. The average cost per live birth was estimated to 
be € 6,787 for Gonal-f and € 7,449 for Bemfola. Furthermore, Gonal-f generated an 
ICER equal to € 1,210 compared to Bemfola, which is the additional cost required 
for Gonal-f to gain an additional live birth in comparison with Bemfola. Gonal-f, 
although it has a higher acquisition cost in comparison with Bemfola, provides a 
lower average cost per live birth and an ICER of € 1,210. ConClusions: The results 
of this cost-effectiveness analysis indicate that Gonal-f is a cost-efficient treat-
ment strategy for the Italian health service compared to Bemfola in the treatment 
of infertility.
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Cost-EffECtIvEnEss of nExPlAnon® (EtonogEstrEl ImPlAnt) 
ComPArEd to otHEr rEImBursEd ContrACEPtIvE mEtHods In frAnCE 
BAsEd on rEAl lIfE dAtA
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objeCtives: To estimate the cost-effectiveness of Nexplanon (etonogestrel 
implant) compared to other reimbursed contraceptive methods in 
France. Methods: A 6 year cost effectiveness model was developed to assess the 
cost per unplanned pregnancy of different reimbursed methods (oral contracep-
tive pill (COC), hormonal intrauterine device (IUD), copper IUD and Nexplanon® 
among French women in the perspective of the French health care system. Efficacy 
inputs, including rate of pregnancies and discontinuation, as well as economic 
parameters of the model were estimated through an analysis of French claim 
database named EGB based on 2012 data (FACET study). Outcomes considered 
for contraceptive failure were birth, extra-uterine pregnancy, miscarriage and 
abortion. Costs of contraception and failures included device, drugs, exams and 
medical management (physician visits, procedures and hospitalizations) as 
reported in the database. A discount rate of 4% was applied to both efficacy and 
objeCtives: At the most European countries the cost for assisted reproduc-
tive technology (ART) are compensated from state and insurance funds. At the 
first in Ukraine state funding of ART was launched on the Orders of MoH №579 
from 24.11.2004. However, most patients have to pay own out-of-pocket costs for 
ART. Methods: We evaluated the general cost of short and long stimulation pro-
tocols for ART of new Order of MOH Ukraine №771 from 23.12.2008 “On Approval 
of Instruction on the use of assisted reproductive technologies”. Cost analysis for 
short and long protocols, based on the comparison of costs during 2014 and 2015 in 
Ukraine. Results: We used the prices from database Morion (Kiyv) on 01.04.2015 
and analysed the cost for short protocol. The stimulation of superovulation with 
Puregon was 18000 UAH (1Euro= 24.7 UAH) or with Elonva was 13 000 UAH. Also 
cost on other medicines were included. In average, a general cost per 1 cycle was 
16 600 UAH. Were analyzed the cost of ART long protocol. We included the cost 
with Diferelin depot that was 2800 UAH. The cost of stimulation of superovulation 
with Puregon was 18000 UAH. In average, a general cost per 1 cycle was 24 000 UAH. 
We compared the cost data on ART during 2014-2015. The average salary was 3998 
UAH on 01.04.2015 in Ukraine. ConClusions: Comparing data 2014 and 2015 were 
founded, that the cost of short protocol increased by 27% and by 41% the long one. 
It was established that the cost of ART are high. Revealed that the cost of ART is 4-6 
times higher than the average salary, therefore the availability of ART for families 
is low. It is necessary to determine the budget financing for ART to improve access 
to ART in Ukraine.
PIH15
AnAlysIs of PrEEClAmPsIA PrEvEntIon In rEAl PrACtICE And tHE nEEd 
to ImProvE InformAtIon suPPort of doCtors In ukrAInE
Maksymovych N, Zalis’ka O, Horbachevska K
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
objeCtives: Preeclampsia has a high prevalence rate and it’s the second leading 
cause of maternal mortality. In developing countries a preeclampsia is the cause of 
50 000 deaths each year. An effective method of preeclampsia prevention in accord-
ance with WHO guidelines, is a prescription of antiplatelet drugs. Methods: 
Analysis of consumed drugs for pregnant women, according to the real practice 
of the district hospital in Lviv region during 2014. Systematization of evidence 
data about the effectiveness of prevention and treatment of preeclampsia, which 
were published in the databases Cochrane, Pubmed, ClinicalTrials.gov Results: 
The analysis of 112 medical records pregnant inpatients, who were hospitalized 
in September-December 2014, were conducted. For 42 (38%) patients were diag-
nosed the preeclampsia. For treatment intended antiplatelet drugs for 17 patients 
that only 40% were taking effective treatment. Other patients received various 
vitamins and antioxidants that have not confirmed evidence-effectiveness. The 
analysis of databases showed that recent RCTs (2013) indicate that antiplatelet 
therapy reduced the risk of pre-eclampsia by 21%. In randomize studies found 
that reduced level of neonatal mortality on 16% and the frequency of children 
born with low birth weight on 8%. In Ukraine, were registered 23 trade names of 
aspirin, including 11 from ukranian manufacturers. We calculated the costs of 
prevention during 5 months per patient (1 USD= 22,3 UAH on 30.05.2015). Costs 
ranged from 3,10 USD to 15,5 USD. The best choice of affordable was aspirin in 75 
mg with total costs 4,67 USD. ConClusions: We established that treatment with 
low doses of aspirin 75 mg / day in early pregnancy for women with high risk of 
preeclampsia is an effective prevention of preeclampsia. In Ukraine the patients 
have to pay out of pocket , than the necessary information support of doctors in 
hospitals on effective and affordable prevention of preeclampsia by antiplatelet 
schemes.
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Cost-EffICIEnCy of of nAtIonAl drug InformAtIon CEntEr tHrougH 
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objeCtives: National Drug Information Center (NDIC) has started providing ser-
vices since January 2013; and answering public and professional inquires through 
MOH-Hotline Calling Services (937) since December 2013. The objective of this study 
was to estimate cost-efficiency of NDIC in Saudi Arabia using American model 
of drug information inquires cost avoidance. Methods: Simulation including 
all 12-month 2014 of receiving adults and pediatrics drug information inquiries 
through MOH-Hotline Calling Services (937). Ten on-call clinical Pharmacists and 
expert trained pharmacists were receiving calls from public and professional asking 
about drug information, through manual documentation system of drug informa-
tion inquiries by data collecting form. Using international Study Model (Kinky et 
al, Ann Pharmacother 1999), the cost considered were the expected results of drug 
related problems sequel of drug information inquires if not existing drug infor-
mation services and were not answered; starting from Physician visit, additional 
treatment, hospital admission to death stage. Results: The total number answered 
calls were 976 calls, with 264 (27%) answered calls were documented; the aver-
age costs avoidance per each answered call was (415.78 USD), and total cost was 
(109,768 USD) with partial documentation, the estimated total cost with complete 
documentation was (405,801 USD) per year. The cost avoidance of answering public 
inquiries was (80,806.5 USD) and Professional inquires was (28,961.5 USD). The high-
est cost avoidance based on type of inquires was dose standardization (34,195 USD), 
drug administration (21,324 USD) followed by drugs in pregnancy (15,826 USD) and 
Adverse a Drug reaction (12,793 USD). The highest cost avoidance was Antibacterial 
expected related problem (33,454.5 USD) ConClusions: In this National Drug 
Information Center cost-efficiency simulation for Saudi Arabia, hotline line calling 
services - Drug Information associated with cost savings per each receiving call. 
expanding the answering drug information services with electronic documentation, 
